Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vemlidy
Vemlidy 25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5
HOS-135904 · Präparat HOS-097792
This medicinal product should not be co-administered with medicinal products containing tenofovir
disoproxil, tenofovir alafenamide or adefovir dipivoxil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-31T09:05:00Z · SHA-256 fe69ec0120bf519ffbfbc733bef6aef6622c9f34191c9918790e7ff2aa064333 · Passage 7dee0dc180d01913e840dbc3fb54256bec22979dfeea943e518fa7143332fca3 · Zeichen 57–211 im Abschnitt
Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka
Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-136578 · Präparat HOS-097888
Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other
medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or other
cytidine analogues, such as lamivudine (see section 4.4). Emtricitabine/Tenofovir disoproxil Krka
should not be administered concomitantly with adefovir dipivoxil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir dipivoxil (HOS-110478) tenofovir alafenamide (HOS-110476) lamivudine (HOS-085829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage 1b39213e1feabdc0a4b4dba8bfbff50b4546a0ef180824b9d5f286e998a6f35b · Zeichen 769–1122 im Abschnitt
Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka
Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–14
HOS-136585 · Präparat HOS-097888
11
Lamivudine/Tenofovir disoproxil Lamivudine: Lamivudine and
AUC: ↓ 3% (↓ 8% to ↑ 15) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 24% (↓ 44 to ↓ 12) Krka should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 4% (↓ 15 to ↑ 8)
Cmax: ↑ 102% (↓ 96 to ↑ 108)
Cmin: NC
Efavirenz/Tenofovir disoproxil Efavirenz: No dose adjustment of efavirenz is
AUC: ↓ 4% (↓ 7 to ↓ 1) required.
Cmax: ↓ 4% (↓ 9 to ↑ 2)
Cmin: NC
Tenofovir:
AUC: ↓ 1% (↓ 8 to ↑ 6)
Cmax: ↑ 7% (↓ 6 to ↑ 22)
Cmin: NC
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Adefovir dipivoxil /Tenofovir Adefovir dipivoxil: Adefovir dipivoxil and
disoproxil AUC: ↓ 11% (↓ 14 to ↓ 7) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 7% (↓ 13 to ↓ 0) Krka should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 2% (↓ 5 to ↑ 0)
Cmax: ↓ 1% (↓ 7 to ↑ 6)
Cmin: NC
Hepatitis C virus (HCV) antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ 74 to ↑ 121) tenofovir resulting from co-
Atazanavir/Ritonavir Cmax: ↑ 68% (↑ 54 to ↑ 84) administration of tenofovir disoproxil,
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% (↑ 91 to ↑ 150) ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: atazanavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↔ adverse reactions related to tenofovir
Cmax: ↔ disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↑ 42% (↑ 34 to ↑ 49) ritonavir or cobicistat) has not been
Atazanavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↑ 63% (↑ 45 to ↑ 84) if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 45% (↑ 27 to ↑ 64)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↔
Cmax: ↑ 47% (↑ 37 to ↑ 58)
Cmin: ↑ 47% (↑ 38 to ↑ 57)
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↔ tenofovir resulting from co-
Darunavir/Ritonavir Cmax: ↔ administration of tenofovir disoproxil,
(800 mg q.d./100 mg q.d.) + Cmin: ↔ ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: darunavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↓ 27% (↓ 35 to ↓ 18) adverse reactions related to tenofovir
12
Cmax: ↓ 37% (↓ 48 to ↓ 25) disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↔ ritonavir or cobicistat) has not been
Darunavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↔ if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 48% (↑ 34 to ↑ 63)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 50% (↑ 42 to ↑ 59)
Cmax: ↑ 64% (↑ 54 to ↑ 74)
Cmin: ↑ 59% (↑ 49 to ↑ 70)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↓ 34% (↓ 41 to ↓ 25) The increased exposure of tenofovir
Efavirenz/Emtricitabine/Tenofovir Cmax: ↓ 34% (↓ 41 to ↑ 25) could potentiate adverse reactions
disoproxil Cmin: ↓ 34% (↓ 43 to ↑ 24) associated with tenofovir disoproxil,
(600 mg/200 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Efavirenz:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 98% (↑ 77 to ↑ 123)
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↔ The increased exposure of tenofovir
Emtricitabine/Rilpivirine/ Tenofovir Cmax: ↔ could potentiate adverse reactions
disoproxil Cmin: ↔ associated with tenofovir disoproxil,
(200 mg/25 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Rilpivirine:
AUC: ↔
Cmax: ↔
13
Cmin: ↔
Tenofovir:
AUC: ↑ 40% (↑ 31 to ↑ 50)
Cmax: ↔
Cmin: ↑ 91% (↑ 74 to ↑ 110)
Ledipasvir/Sofosbuvir Sofosbuvir: No dose adjustment is required. The
(90 mg/400 mg q.d.) + Dolutegravir AUC: ↔ increased exposure of tenofovir could
(50 mg q.d.) + Cmax: ↔ potentiate adverse reactions associated
Emtricitabine/Tenofovir disoproxil with tenofovir disoproxil, including
(200 mg/245 mg q.d.) GS-3310072 renal disorders. Renal function should
AUC: ↔ be closely monitored (see section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) dolutegravir (HOS-089992) hepatitis C virus (HOS-108813) lamivudine (HOS-085829) rilpivirine (HOS-088090) darunavir (HOS-086181) hepatitis B virus (HOS-113725) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage ef1a7c3e42b38e99972a859eaae7af1573783b27f7b434b743e8cd7a9897fd81 · Zeichen 7896–17795 im Abschnitt
Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-139267 · Präparat HOS-098314
Biktarvy should not be administered concomitantly with medicinal products containing tenofovir
alafenamide, tenofovir disoproxil, lamivudine or adefovir dipivoxil used for the treatment of
HBV infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 0d1281b0a047c35981d784837f76b76b654aef7e30b993f848390e0ebdedd2a7 · Zeichen 57–260 im Abschnitt
Wechselwirkungen · Entecavir Accord
Entecavir Accord 0.5 mg film-coated tablets Entecavir Accord 1 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-139474 · Präparat HOS-098352
Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with
medicinal products that reduce renal function or compete for active tubular secretion may increase
serum concentrations of either medicinal product. Apart from lamivudine, adefovir dipivoxil and
tenofovir disoproxil fumarate, the effects of coadministration of entecavir with medicinal products that
are excreted renally or affect renal function have not been evaluated. Patients should be monitored
closely for adverse reactions when entecavir is coadministered with such medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir dipivoxil (HOS-110478) lamivudine (HOS-085829) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-24T18:04:00Z · SHA-256 97367d33a6e7bed722b69929ac73a618adf363304423f3a6b92163ac4b075123 · Passage ef6e707db8bf020283aef0686fde0997ef114b457c47c0f7e75e63cded1ae9f1 · Zeichen 0–591 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.